Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

NCT00083993 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1236

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Neoplasm Metastasis

Interventions

DRUG: Temsirolimus (CCI-779) for 34 months
DRUG: Letrozole for 34 months

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer